The much-anticipated results of TauRx‘s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients.
According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s is therefore quickly becoming a major global health concern.
Based in Aberdeen (Scotland), TauRx has one of the most advanced and promising candidates for Alzheimer’s among recent breakthroughs in the field.
This candidate is LMTX, which reduces the levels of aggregated misfolded tau proteins – considered a key drivers of Alzheimer’s disease and neurodegeneration.
Now, the first results from Phase III have been announced.